Sanofi invests $700 million in genetic medicines
Sanofi's subsidiary Genzyme has expanded its partnership with Alnylam Pharmaceuticals to develop drugs for rare genetic diseases.
The $700 million investment will give Genzyme/Sanofi a 12 per cent share of Alnylam, and access to its drug candidates - for example, its phase 2 familial amyloid cardiomyopathy treatment.
Related news:
Sanofi pays $700 million for Alnylam drugs and stake (Bloomberg).
Sanofi to buy 12 percent of Alnylam, expands rare-disease drug deal (Reuters).
Reference link:
Genzyme and Alnylam expand collaboration on rare genetic diseases (Sanofi press release).